Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Dapi Road, Niao-Sung District, Kaohsiung City, 833, Taiwan.
Department of Endocrinology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
BMC Pharmacol Toxicol. 2017 Jun 5;18(1):41. doi: 10.1186/s40360-017-0148-3.
Tardive akathisia (TA) is a subtype of tardive syndrome, and its etiology is still uncertain. Sevikar is an anti-hypertensive agent containing both amlodipine and olmesartan, and has never been reported to have an adverse reaction in patients with tardive syndrome.
A 57-year-old woman who took Sevikar for hypertension for 10 years developed TA one and a half years before receiving any psychiatric treatment. After switching from Sevikar to bisoprolol, she reported obvious improvement in her akathisia.
It is noteworthy that her TA developed before receiving any antidepressant medication, and that her TA improved after discontinuation of Sevikar. In light of these pharmacodynamic properties, it is therefore concluded that use of amlodipine and olmesartan might have caused TA in this patient. We reported this rare case to remind clinicians to be aware of possible akathisia when using amlodipine and olmesartan in combination as anti-hypertensive agents.
迟发性运动障碍（TA）是迟发性综合征的一种亚型，其病因仍不确定。塞瓦卡（Sevikar）是一种含氨氯地平和奥美沙坦的抗高血压药物，从未有过在迟发性综合征患者中出现不良反应的报道。
一位 57 岁女性因高血压服用塞瓦卡 10 年，在接受任何精神科治疗前一年半出现 TA。将塞瓦卡换用比索洛尔后，她的运动障碍明显改善。
值得注意的是，她的 TA 在服用任何抗抑郁药之前就已经出现，并且在停用塞瓦卡后得到了改善。鉴于这些药效学特性，因此可以得出结论，在该患者中，使用氨氯地平和奥美沙坦可能导致了 TA。我们报告这个罕见病例是为了提醒临床医生在使用氨氯地平和奥美沙坦作为抗高血压药物时要注意可能出现的运动障碍。
